We're focusing on a vaccination roll-out to build our resilience and to continue to ensure that we remain in the position that we are in, a very fortunate one. Our focus on a vaccination roll-out will continue to build our defence and ensure that we can keep our people safe, keep the economy going, and look towards our recovery. There is $1.5 billion allocated to the COVID-19 vaccine—and we know Pfizer is the vaccine of preference here in New Zealand—and our immunisation programme, including just over $1 billion for our advance purchase agreements for vaccines and $357 million for the immunisation programme. 